The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes comparison between the MET inhibitors (METi) capmatinib and tepotinib in patients with stage IV non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.
 
Guilherme Sacchi de Camargo Correia
No Relationships to Disclose
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Yujie Zhao
Employment - Mayo Clinic; Mayo Clinic
Honoraria - Coherus Biosciences; Lilly
Consulting or Advisory Role - Coherus Biosciences; Lilly
Research Funding - Alpine Immune Sciences (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology; Pfizer (Inst); Zai Lab
 
Shenduo Li
No Relationships to Disclose
 
Vinicius Ernani
Consulting or Advisory Role - AstraZeneca/MedImmune; Daiichi Sankyo/Astra Zeneca; Jazz Pharmaceuticals; Novocure
Research Funding - AstraZeneca/MedImmune
 
Konstantinos Leventakos
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Mirati Therapeutics (Inst); MJH Life Sciences (Inst); OncLive (Inst); Regeneron (Inst); Takeda (Inst); Targeted Oncology (Inst)
Research Funding - AstraZeneca (Inst); Mirati Therapeutics (Inst)
 
Aaron Scott Mansfield
Honoraria - Roche
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genzyme (Inst); Gilead Sciences (Inst); Janssen (Inst); Johnson & Johnson Global Services (Inst); Takeda (Inst)
Speakers' Bureau - Chugai/Roche (Inst)
Research Funding - Bristol Myers Squibb (Inst); Novartis (Inst); Verily (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
Other Relationship - Mesothelioma Applied Research Foundation
 
Kaushal Parikh
Consulting or Advisory Role - Guardant Health; Jazz Pharmaceuticals (Inst); MJH Life Sciences
Research Funding - Pfizer
 
Anastasios Dimou
Honoraria - Intellisphere; Intellisphere (Inst); Intellisphere (Inst); Roche/Genentech
Consulting or Advisory Role - Anheart Therapeutics; ChromaCode; Guardant Health (Inst); TP Therapeutics (Inst)
Research Funding - Anheart Therapeutics (Inst); AstraZeneca (Inst); Guardant Health; Merck; Novartis (Inst); Sorrento Therapeutics (Inst); Syntrix Biosystems (Inst)
Travel, Accommodations, Expenses - Guardant Health
Other Relationship - Rising Tide Foundation (Inst)
 
Rami Manochakian
Consulting or Advisory Role - Alpha 2; AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Daiichi Sankyo inc; Guardant Health; Janssen; Novocure; Oncohost; Takeda; Turning Point Therapeutics